Angiotech shares drop on report of lower stent use
TORONTO (Reuters) - Shares of Angiotech Pharmaceuticals fell more than 6 percent on Thursday after the Wall Street Journal reported a decline in the use of drug-coated stents at several major hospitals.
Shares of Angiotech, whose main revenue has come from making a drug coating for Boston Scientific's stents, were down 69 Canadian cents, or 4.9 percent, at C$13.40 on volume of 159,000 shares. Earlier in the session, they dropped as low as C$13.15
· Read The Full Boston Scientific Taxus Stent Article From Reuters -->
·
Read All Boston Scientific Taxus Stent News Stories -->